ESPE2024 Poster Category 2 Growth and Syndromes (39 abstracts)
A child with cutaneous-skeletal hypophosphatemia syndrome caused by a mosaic HRAS mutation – outcome of treatment with anti-FGF23 antibody
Jing Wu , Qiaoyu Cao , Wei Lu , Chengjun Sun , Qiuyue Li , Rong Ye , Ruoqian Cheng , Feihong Luo & Ming Li
Children's Hospital of Fudan University, Shanghai, China
Cutaneous-skeletal hypophosphatemia syndrome (CSHS) is a rare inherited disorder that causes bone abnormalities due to hypophosphatemic rickets, which is a significant health comorbidity. Conventional therapy involving multiple daily oral doses of phosphate and calcitriol for CSHS rickets has limited effectiveness. We present the clinical features and therapeutic outcomes of the first Chinese child with bone fractures, a seizure history, and novel recurrent gastrointestinal manifestations of CSHS, including diarrhea and bowel obstruction. The effectiveness of conventional therapy and anti-FGF-23 antibody (burosumab) was evaluated. High-throughput DNA sequencing was performed on the patient's blood DNA, skin tissue, oral mucosa, and hair follicles to identify causative mutations. The child had a tissue-differentiated somatic activating HRAS p.G13R mutation. Burosumab resulted in a steady increase in blood phosphorus levels and a significant improvement in the patient's clinical symptoms and physical function compared to conventional phosphate therapy. It is suggested that younger children may receive a higher initial dosage of burosumab for better outcomes. However, long-term follow-up is still necessary to confirm its efficacy and safety.
Key words: cutaneous skeletal hypophosphatemia syndrome; HRAS; mosaicism; fibroblast growth factor-23; burosumab
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more